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We read with interest the recent paper of Hindle, Rostron and Gatti describing an automated serum fructosamine method and found some discrepancies from our own experience that require comment.
Most importantly, we used a buffer comprising 75 mmol Na2C03 plus 25 mmol NaHC0 3 per litre which, notwithstanding previous assertions, gives a pH of 10·35. This difference in pH probably accounts for the higher activity of DMF standards described by Hindle et al. Moreover, the reducing activity of DMF (now commercially available from Sigma Chemical Co.) is much more sensitive than serum to changes in pH. 2 This is the probable reason why Hindle et al.
observed lower serum values than we had previously reported.i" The increased formazan production at the more alkaline pH may also have been responsible for the non-linearity that they observed in their standard curves.
We recognised the effect of albumin concentration on the reaction between DMF and NBT and opted to keep albumin in the standards constant at 40 g/L, 2We have also observed marked variation in the reducing activity of different albumin preparations as noted by Hindle et al. and now correct for albumin activity in the zero standard by using the slope of the standard plot as a calibration factor. Comparison of Figs I and 2 of Hindle et al. shows that with albumin at 40 g/L, the slopes (say up to 5 mmol DMF/L) are the same despite the difference in absorbance readings. This confirms our own findings.
Application of the fructosarnine test, both to diabetes detection programmes and in monitoring established diabetic patients, requires stable and reproducible standards if results from different laboratories are to be compared. Calibration of the assay by absorbance change, as suggested by Hindle et al., does not take into account variability in the reagent or analytical procedure, and would be prone to inaccuracy in the long term. DMF has the merit of being available in pure crystalline form, stable at room temperature and showing similar reducing activity to that of serum under rigorously standardised reaction conditions. However, in routine operation, we have found secondary standards of glycated albumin to be more robust with less interbatch The authors reply as foUows:
We found that the reference method described by Johnson, Metcalf and Baker! was, in general, difficult to follow, since it contained statements which were liable to misinterpretation. However, the composition of the reagent was quite clearly stated ['carbonate buffer (0·1 mol/I, pH 10,8)']. The pH was referred to directly on four, and implied on three, further occasions, and no alteration to the method, with the exception of instrumentation, was described in subsequent papers. [2] [3] [4] In the New Zealand group's most recent publication" the reagent was said to be carbonate buffer, pH 10·35 (0·1 M). This was the first indication that the reagent composition may have been altered. There was no indication that the previous analyses had also been conducted at this pH, particularly as their quoted reference ranges had all been similar. However, a recent personal communication from Dr Baker states that the reference method I was 'incorrect, the pH of the carbonate buffer should have read 10·35'.
Ms Lawson and Dr. Baker (personal communication) state that at pH 10·35 glucose interference is not significant, when Johnson et at' found that 'glucose caused a significant reduction of NBT above pH 11, and lowering the pH to between 10·5 and 11·0 removed interference'. The effect of other reducing substances on NBT at pH 10·8 was also investigated. Are we to assume that these observations also may be incorrect?
We agree with all the New Zealand group's observations regarding differences between our data and theirs, which is partly due to the pH difference. Moreover, an albumin blank correction, which was said to be insignificar.t for practical purposes I is now applied, and this would also result in higher values than our own, where blank correction is not performed. Other groups", also using reagent, pH 10,8, have applied albumin blank correction to obtain values which approach those of the New Zealand group.
Our suggestion that absorbance change alone could be used instead of DMF for quantitation of the reduction of NBT was speculative, since DMF was not readily available when our paper was written and many different groups were making their own preparations of doubtful and varying quality. DMF also bears little resemblance to glycosyl-protein. We agree absolutely about standardisation, and have for some time used secondary serum standards.
Many laboratories are investigating the fructosamine assay based on the reference method I and we feel it is important that the New Zealand group should clearly define the exact conditions used in their various publications, stating when and how their methodology changed.
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